Blood mRNA levels of T cells and IgE receptors are novel non-invasive biomarkers for eosinophilic esophagitis (EoE)

Venkateshaiah, Sathisha Upparahalli; Rayapudi, Madhavi; Kandikattu, Hemanth Kumar; Yadavalli, Chandra Sekhar; Mishra, Anil

doi:10.1016/j.clim.2021.108752

Cited by 4 publications

(5 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Available online at: https://www. accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=237507 peripheral blood IL-15Ra mRNA levels are reduced, seemingly indicating that most of the cells expressing IL-15Rα moved to the tissue (Upparahalli Venkateshaiah et al, 2021).…”

Section: Interleukin-15mentioning

confidence: 99%

“…Indeed, increased esophageal iNKTs have been repeatedly reported in EoE pediatric and adult patients, especially in the active state of the disease ( Jyonouchi et al, 2013 ; Rayapudi et al, 2014 ) and in early-onset patients ( Lexmond et al, 2014 ). This esophageal increase is associated with a reduction of peripheral blood iNKTs ( Upparahalli Venkateshaiah et al, 2021 ). This could be explained by iNKT cells homing in the tissue via receptor CXCR6 and esophageal epithelial cells have been described as the source of CXCL16 ( Rayapudi et al, 2014 ).…”

Section: Focus On Type 2 Inflammation: the Protagonistsmentioning

confidence: 99%

“…Invariant Natural Killer T cells neutralization via anti-mCD1d or anti-hVα14Jα18 antibodies protected against the development of EoE in a murine model based on intranasal peanut and Aspergillus sensitization ( Upparahalli Venkateshaiah et al, 2021 ). Consequently, iNKT cell neutralization by humanized anti-CD1d and anti-Vα24Jα18 antibodies has been suggested as a potential therapy for human EoE but no studies on humans been proposed yet.…”

Section: Focus On Type 2 Inflammation: the Protagonistsmentioning

confidence: 99%

“…IL-15 and its receptor IL-15Ra are elevated in esophageal tissue samples of patients with EoE, as well as in an intranasal Aspergillus -induced murine model of EoE, and correlate with esophageal eosinophilia ( Zhu et al, 2010 ). Interestingly, peripheral blood IL-15Ra mRNA levels are reduced, seemingly indicating that most of the cells expressing IL-15Rα moved to the tissue ( Upparahalli Venkateshaiah et al, 2021 ).…”

Section: Focus On Type 2 Inflammation: the Protagonistsmentioning

confidence: 99%

“…TNF-α derived from dendritic cells, eosinophils, mast cells and T cells is able to induce epithelial cell contraction, migration, and collagen secretion, as well as the expression of adhesion molecules on endothelial cells ( Straumann et al, 2001 ; Rieder et al, 2014 ; Upparahalli Venkateshaiah et al, 2021 ). These aspects may link this cytokine to tissue remodeling and angiogenesis in EoE patients.…”

Section: Focus On Type 2 Inflammation: the Protagonistsmentioning

confidence: 99%

See 4 more Smart Citations

Type 2 Inflammation in Eosinophilic Esophagitis: From Pathophysiology to Therapeutic Targets

et al. 2022

View full text Add to dashboard Cite

Eosinophilic esophagitis (EoE) is a chronic immune-mediated disease of the esophagus characterized clinically by symptoms related to esophageal dysfunction and histologically by eosinophil-predominant inflammation, whose incidence is rising. It significantly affects patients’ quality of life and, if left untreated, results in fibrotic complications. Although broad consensus has been achieved on first-line therapy, a subset of patients remains non-responder to standard therapy. The pathogenesis of EoE is multifactorial and results from the complex, still mostly undefined, interaction between genetics and intrinsic factors, environment, and antigenic stimuli. A deep understanding of the pathophysiology of this disease is pivotal for the development of new therapies. This review provides a comprehensive description of the pathophysiology of EoE, starting from major pathogenic mechanisms (genetics, type 2 inflammation, epithelial barrier dysfunction, gastroesophageal reflux, allergens, infections and microbiota) and subsequently focusing on the single protagonists of type 2 inflammation (involved cells, cytokines, soluble effectors, surface proteins and transcription factors) that could represent present and future therapeutic targets, while summarizing previous therapeutic approaches in literature.

show abstract

Section: Interleukin-15mentioning

confidence: 99%

Section: Focus On Type 2 Inflammation: the Protagonistsmentioning

confidence: 99%

Section: Focus On Type 2 Inflammation: the Protagonistsmentioning

confidence: 99%

Section: Focus On Type 2 Inflammation: the Protagonistsmentioning

confidence: 99%

Section: Focus On Type 2 Inflammation: the Protagonistsmentioning

confidence: 99%

See 3 more Smart Citations

Type 2 Inflammation in Eosinophilic Esophagitis: From Pathophysiology to Therapeutic Targets

et al. 2022

View full text Add to dashboard Cite

show abstract

Molecules involved in the development of Barrett’s esophagus phenotype in chronic eosinophilic esophagitis

Venkateshaiah

Yadavalli

Kandikattu

et al. 2022

American Journal of Physiology-Gastrointestinal and Liver Physi

View full text Add to dashboard Cite

Objectives: Investigate the molecules involved in development of Barrett's esophagus (BE) in human EoE. Methods: Histopathological, immunohistochemical, real-time PCR and ELISA analyses are performed to identify the signature genes and proteins involved in the progression of BE in EoE. Results: We detected characteristic feature of BE like intermediate columnar type epithelial cells, induced BE signature genes like ErbB3, CDX1, ErbB2IP in the esophageal mucosa of EoE patients. In addition, we several BE associated diagnostic proteins TFF3, p53 and the progression marker like EGFR, p16, MICA, MICB and MHC molecules in esophageal biopsies of chronic EoE patients. Interestingly, we also detected mucin-producing columnar cells and MUC-2, MUC-4 and MUC5AC genes and proteins along with induced IL-9 in chronic EoE patients. A strong correlation of IL-9 with mucin genes are observed that implicated a possible role for IL-9 in the transformation of esophageal squamous epithelial cells to columnar epithelial cells in EoE patients. These findings indicates that IL-9 may has an important role in BE development in chronic EoE patients. Furthermore, our in vitro data of IL-9 exposure to primary esophageal epithelial cells provide evidence that IL-9 is involved in the induction mucins producing and epithelial barrier cells transcripts and proteins like CK8/18. GATA4, SOX9, TFF1, MUC5AC, including tight junction proteins. Conclusions: Taken together, these findings provide evidence that indeed IL-9 has a role in the initiation and progression of BE characteristics like development of mucin producing columnar epithelial cells in chronic EoE patients.

show abstract

Mechanistic Insights into Eosinophilic Esophagitis: Therapies Targeting Pathophysiological Mechanisms

Massironi,

Mulinacci,

Gallo

et al. 2023

Cells

View full text Add to dashboard Cite

Eosinophilic esophagitis (EoE) is a chronic inflammatory disease characterized by eosinophilic infiltration of the esophagus. It arises from a complex interplay of genetic predisposition (susceptibility loci), environmental triggers (allergens and dietary antigens), and a dysregulated immune response, mainly mediated by type 2 T helper cell (Th2)-released cytokines, such as interleukin (IL)-4, IL-5, and IL-13. These cytokines control eosinophil recruitment and activation as well as tissue remodeling, contributing to the characteristic features of EoE. The pathogenesis of EoE includes epithelial barrier dysfunction, mast cell activation, eosinophil degranulation, and fibrosis. Epithelial barrier dysfunction allows allergen penetration and promotes immune cell infiltration, thereby perpetuating the inflammatory response. Mast cells release proinflammatory mediators and promote eosinophil recruitment and the release of cytotoxic proteins and cytokines, causing tissue damage and remodeling. Prolonged inflammation can lead to fibrosis, resulting in long-term complications such as strictures and dysmotility. Current treatment options for EoE are limited and mainly focus on dietary changes, proton-pump inhibitors, and topical corticosteroids. Novel therapies targeting key inflammatory pathways, such as monoclonal antibodies against IL-4, IL-5, and IL-13, are emerging in clinical trials. A deeper understanding of the complex pathogenetic mechanisms behind EoE will contribute to the development of more effective and personalized therapeutic strategies.

show abstract

Blood mRNA levels of T cells and IgE receptors are novel non-invasive biomarkers for eosinophilic esophagitis (EoE)

Cited by 4 publications

References 37 publications

Type 2 Inflammation in Eosinophilic Esophagitis: From Pathophysiology to Therapeutic Targets

Type 2 Inflammation in Eosinophilic Esophagitis: From Pathophysiology to Therapeutic Targets

Molecules involved in the development of Barrett’s esophagus phenotype in chronic eosinophilic esophagitis

Mechanistic Insights into Eosinophilic Esophagitis: Therapies Targeting Pathophysiological Mechanisms

Contact Info

Product

Resources

About